Shanghai Origincell Biological Cryo Equipment Co., Ltd. announced that it will raise CNY 342,440,000 on December 18, 2020. The company entered in to capital Increase agreement with 12 investors including included participation from returning investors Shanghai Shengsen Investment Center (Limited Partnership) for 47,2500,000 for 4% stake to hold 9.7% from 5.7% stake, Shanghai Senjing Investment Center (Limited Partnership) for CNY 29,750,000 for 2.55% stake to hold 6.08% stake from 3.53% stake , Shanghai Hongsen Investment Center (Limited Partnership) for CNY 33,950,000 for 2.94% stake to hold 6.91% stake from 3.97% stake, Shanghai Senchun Investment Center (Limited Partnership) for CNY 25,760,000 for 2.16% to hold 5.32% stake from 3.16% stake, Shanghai Senliang Investment Center (Limited Partnership) for CNY 16,000,000 for 1.44% stake to hold 3.2% stake from 1.76% stake, Shanghai Senwei Investment Center (Limited Partnership) for CNY 13,200,000 for 0.98% stake to hold 2.86% stake from 1.88% stake.

New investors Canature Health Technology Group Co., Ltd. (SZSE:300272) for CNY 45,500,000 for 6.57% stake, Lishui Senyuanchang Enterprise Management Center (Limited Partnership) for CNY 63,000,000 for 9.1% stake, , Shanghai Zengjing Biotechnology Co., Ltd. for CNY 28,000,000 for 4.04% stake, Nanjing Qingsong Medical Treatment Health Industry Investment Partnership Enterprise (Limited Partnership) for CNY 10,010,000 for 1.45% stake, Shanghai Zhangjiang Torch Venture Capital Co., Ltd. for CNY 10,010,000 for 1.45% stake, Deluxe Family Co., Ltd. for CNY 10,010,000 for1.45% stake, and Qingdao Chuanjiu Yuanjing Phase III Equity Investment Fund Partnership (Limited Partnership) for CNY 10,010,000 for 1.45% stake. The transaction was approved by board of directors in the 4th meeting of the 5th directorate of Canature Health Technology Group Co., Ltd. The registered capital of company will increase by CNY 97,840,000.